International Cancer Conference Journal最新文献_第2页

Complete remission of unresectable advanced esophageal squamous cell carcinoma following nivolumab immunotherapy after chemoradiotherapy: a case report. 放化疗后纳武单抗免疫治疗后不可切除的晚期食管鳞状细胞癌完全缓解：1例报告。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-05-23 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00773-y

Ryohei Nishiguchi, Takeshi Shimakawa, Shinichi Asaka, Masako Ogawa, Masano Sagawa, Sachiyo Okayama, Kotaro Kuhara, Takebumi Usui, Hajime Yokomizo, Shunichi Shiozawa

{"title":"Complete remission of unresectable advanced esophageal squamous cell carcinoma following nivolumab immunotherapy after chemoradiotherapy: a case report.","authors":"Ryohei Nishiguchi, Takeshi Shimakawa, Shinichi Asaka, Masako Ogawa, Masano Sagawa, Sachiyo Okayama, Kotaro Kuhara, Takebumi Usui, Hajime Yokomizo, Shunichi Shiozawa","doi":"10.1007/s13691-025-00773-y","DOIUrl":"https://doi.org/10.1007/s13691-025-00773-y","url":null,"abstract":"A 65-year-old man presented with dysphagia and was diagnosed with advanced thoracic esophageal squamous cell carcinoma (ESCC, cStage III, cT3N2M0). Initial treatment included three courses of preoperative chemotherapy with the DCF regimen. However, computed tomography (CT) showed tumor progression, leading to esophageal obstruction at the level of the tracheal bifurcation. The patient subsequently underwent chemoradiotherapy (CRT) combining the DCF regimen with radiotherapy (59.4 Gy). While CRT resulted in tumor shrinkage and reduced lymph node metastasis, residual target lesions persisted. As second-line therapy, nivolumab (240 mg/body, biweekly) was initiated. The treatment was well tolerated, with no significant adverse events. After 36 courses of nivolumab, complete response (CR) of both the primary tumor and metastatic lymph nodes was confirmed through CT, PET-CT, and upper gastrointestinal endoscopy. The patient has remained recurrence-free, with no evidence of new metastasis, and continues to maintain favorable clinical progress. A literature review identified only eight cases of CR achieved with nivolumab for advanced esophageal cancer, with only two involving ESCC, both in cases of recurrence after surgery or CRT. This is the first reported case of CR achieved with nivolumab in unresectable advanced ESCC. Despite PD-L1 expression being below 1%, nivolumab elicited a robust antitumor immune response. This case highlights the potential of immunotherapy, even in cases with low PD-L1 expression, for advanced ESCC.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"204-211"},"PeriodicalIF":0.5,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Favorable response to nivolumab combined with radiotherapy for retroperitoneal leiomyosarcoma. 纳武单抗联合放疗治疗腹膜后平滑肌肉瘤疗效良好。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-05-16 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00771-0

Shin Ishihara, Kouya Shiraishi, Akihiko Yoshida, Taisuke Mori, Toshihide Ueno, Hanako Ono, Hitoshi Ichikawa, Shigehiro Yagishita, Shinji Kohsaka, Yasushi Goto, Yasushi Yatabe, Akinobu Hamada, Akira Kawai, Hiroyuki Mano, Shintaro Iwata

{"title":"Favorable response to nivolumab combined with radiotherapy for retroperitoneal leiomyosarcoma.","authors":"Shin Ishihara, Kouya Shiraishi, Akihiko Yoshida, Taisuke Mori, Toshihide Ueno, Hanako Ono, Hitoshi Ichikawa, Shigehiro Yagishita, Shinji Kohsaka, Yasushi Goto, Yasushi Yatabe, Akinobu Hamada, Akira Kawai, Hiroyuki Mano, Shintaro Iwata","doi":"10.1007/s13691-025-00771-0","DOIUrl":"https://doi.org/10.1007/s13691-025-00771-0","url":null,"abstract":"Retroperitoneal sarcoma (RPS) is a biologically heterogeneous tumor and rare malignant mesenchymal soft-tissue neoplasm. Although the 5-year overall survival rate for RPS is approximately 60%-70%, it is quite low for unresectable tumors. Surgery is a standard treatment for RPS. Immune checkpoint inhibitors (ICIs) have shown promising effects against various tumor types; however, the efficacy of ICIs for RPS is unclear and the combination of ICIs with other drugs or treatments has been considered. We report the case of a 71-year-old woman with dual primary cancer, retroperitoneal leiomyosarcoma, and malignant melanoma in the lower leg. Retroperitoneal leiomyosarcoma was considered inoperable and managed with palliative radiotherapy. However, subsequent treatment with nivolumab for melanoma resulted in significant shrinkage of the retroperitoneal leiomyosarcoma. The genomic analysis revealed a low TMB and poor CD8 score. These findings suggest that the retroperitoneal leiomyosarcoma would be immunologically cold. We report an unexpectedly successful treatment of RPS with ICI therapy after radiotherapy. There have been few reports on the detailed genetic profiles of sarcomas that respond to ICI therapy. Our findings suggest that the combination of radiotherapy and ICIs has therapeutic potential for immunologically cold tumors and may be a useful treatment strategy for RPS.Supplementary information: The online version contains supplementary material available at 10.1007/s13691-025-00771-0.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"190-197"},"PeriodicalIF":0.5,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic and clinical challenges of primary pulmonary solid adenocarcinoma with signet-ring cell features: a case report with unusual presentation and literature review. 具有印戒细胞特征的原发性肺实体腺癌的诊断和临床挑战：1例罕见的临床表现和文献复习。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-05-09 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00767-w

Noura A A Ebrahim, Moamen O Othman, Ahmed M Fahmy, Neveen S Tahoun, Rasha A Salama, Nermeen Mostafa Mahmoud, Habiba Elfandy

{"title":"Diagnostic and clinical challenges of primary pulmonary solid adenocarcinoma with signet-ring cell features: a case report with unusual presentation and literature review.","authors":"Noura A A Ebrahim, Moamen O Othman, Ahmed M Fahmy, Neveen S Tahoun, Rasha A Salama, Nermeen Mostafa Mahmoud, Habiba Elfandy","doi":"10.1007/s13691-025-00767-w","DOIUrl":"https://doi.org/10.1007/s13691-025-00767-w","url":null,"abstract":"Solid adenocarcinoma with signet-ring cell features (SRCF) is an extremely rare variant of lung adenocarcinoma, often mimicking metastatic tumors from other sites. Accurate diagnosis relies heavily on immunohistochemical profiling. This report discusses a case of solid adenocarcinoma with SRCF presenting with pleural thickening, highlighting diagnostic challenges and treatment limitations. We report a 36-year-old smoker with progressive dyspnea and pleuritic pain. Imaging revealed pleural thickening and pulmonary nodules. Histopathology showed solid adenocarcinoma with SRCF, confirmed by immunohistochemistry as primary pulmonary signet-ring cell carcinoma (SRCC). Despite chemotherapy, the disease progressed, and the patient succumbed within 3 months. Primary pulmonary solid adenocarcinoma with SRCF is associated with high mortality and diagnostic complexity. Immunohistochemical markers remain pivotal in establishing its pulmonary origin. This case reinforced the urgent need for better diagnostic techniques and therapies.Graphical abstract: ","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"289-295"},"PeriodicalIF":0.5,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer genome profiling of prostate cancer identifies a patient with a novel EFNA1-NTRK1 fusion gene. 前列腺癌的癌症基因组分析鉴定了一个新的EFNA1-NTRK1融合基因的患者。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-05-09 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00769-8

Tomohiro Kanaki, Koji Hatano, Shinichiro Tahara, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Taigo Kato, Atsunari Kawashima, Tsuyoshi Takada, Norio Nonomura

{"title":"Cancer genome profiling of prostate cancer identifies a patient with a novel EFNA1-NTRK1 fusion gene.","authors":"Tomohiro Kanaki, Koji Hatano, Shinichiro Tahara, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Taigo Kato, Atsunari Kawashima, Tsuyoshi Takada, Norio Nonomura","doi":"10.1007/s13691-025-00769-8","DOIUrl":"https://doi.org/10.1007/s13691-025-00769-8","url":null,"abstract":"NTRK gene fusions serve as oncogenic drivers in solid tumors. While these fusions are uncommon in prostate cancer, they can be detected through cancer genome profiling tests. In a study of 68 prostate cancer cases analyzed with comprehensive cancer genome profiling, we identified a single instance of a novel EFNA1-NTRK1 fusion. The patient, a 56-year-old male diagnosed with prostate cancer and bone metastasis, presented with an initial PSA level of 323 ng/mL, a Gleason score of 4 + 4, and was classified as cT3bN0M1b. He underwent combined androgen blockade therapy but progressed to castration-resistant prostate cancer after 31 months. Despite previous treatments with androgen receptor signaling inhibitors and chemotherapies, the cancer continued to advance. Following the identification of an EFNA1-NTRK1 gene fusion via a cancer genome profiling test, the patient received treatment with larotrectinib. Although the initial biopsy showed positive pan-TRK staining in the prostate cancer tissue, the response to larotrectinib was limited in this case.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"296-301"},"PeriodicalIF":0.5,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Two-stage robotic gastrectomy after bypass surgery for a perforated non-curative endoscopic submucosal dissection scar: a case report. 旁路手术后两阶段机器人胃切除术治疗内镜下粘膜夹层穿孔瘢痕：1例报告。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-04-22 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00766-x

Makoto Hikage, Taeko Matsuura, Keiichiro Kawamura, Masato Yamada, Takuya Jimbo, Munetaka Hashimoto, Shunsuke Shibuya, Yasushi Ito, Kazuyuki Kusuda, Yuji Goukon

{"title":"Two-stage robotic gastrectomy after bypass surgery for a perforated non-curative endoscopic submucosal dissection scar: a case report.","authors":"Makoto Hikage, Taeko Matsuura, Keiichiro Kawamura, Masato Yamada, Takuya Jimbo, Munetaka Hashimoto, Shunsuke Shibuya, Yasushi Ito, Kazuyuki Kusuda, Yuji Goukon","doi":"10.1007/s13691-025-00766-x","DOIUrl":"https://doi.org/10.1007/s13691-025-00766-x","url":null,"abstract":"Here, we report a case of scar perforation caused by endoscopic dilation while the patient was waiting for additional gastrectomy after non-curative endoscopic submucosal dissection (ESD) for early gastric cancer. Although conservative treatment prevented the progression of generalized peritonitis, one-stage meticulous surgery was contraindicated because of abscess formation around the pylorus, which is the main target of lymphatic dissection. Therefore, we performed a two-stage surgery. Prior laparoscopic gastrojejunal bypass for peritonitis control and nutritional management allowed for uncompromised curative gastrectomy using a robotic approach. Among the various treatment strategies, our selected two-stage surgery was useful in achieving uncompromised cancer surgery in patients with perforated peritonitis after noncurative ESD, where prophylactic dissection was the primary objective.Supplementary information: The online version contains supplementary material available at 10.1007/s13691-025-00766-x.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"274-279"},"PeriodicalIF":0.5,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hydrogel spacer infection during prostate cancer radiotherapy: a case report of successful abscess management through radical prostatectomy. 前列腺癌放疗期间水凝胶间隔物感染：根治性前列腺切除术成功治疗脓肿1例报告。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-04-16 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00763-0

Hiroki Oshiro, Yu Miyazaki, Takuro Kakehi, Masakatsu Hirano, Yusuke Hama, Maki Kanzawa, Sojun Kanamaru

{"title":"Hydrogel spacer infection during prostate cancer radiotherapy: a case report of successful abscess management through radical prostatectomy.","authors":"Hiroki Oshiro, Yu Miyazaki, Takuro Kakehi, Masakatsu Hirano, Yusuke Hama, Maki Kanzawa, Sojun Kanamaru","doi":"10.1007/s13691-025-00763-0","DOIUrl":"https://doi.org/10.1007/s13691-025-00763-0","url":null,"abstract":"Hydrogel spacers can be inserted to create a gap between the prostate and rectum prior to radiotherapy for prostate cancer, enabling higher radiation doses while reducing rectal toxicity. Spacer infection is relatively rare but significant. We report a case of robot-assisted radical prostatectomy performed for spacer infection and prostate cancer. A 75-year-old man with a hydrogel spacer presented with fatigue and fever after completing 30 Gy of radiation therapy for prostate cancer. He was diagnosed with a periprostatic abscess associated with the hydrogel spacer. Following antibiotic treatment, he underwent robot-assisted radical prostatectomy with concurrent abscess drainage. The treatment outcome was favorable. This case of a radical prostatectomy conducted for spacer infection represents, to our knowledge, the first documented case of management of a hydrogel spacer infection. The favorable treatment outcome suggests that this may be a viable treatment option for similar cases.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"264-268"},"PeriodicalIF":0.5,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Conversion surgery of stage 4 gastric cancer with peritoneal dissemination after overcoming immune-related liver injury: a case report and literature review. 克服免疫相关性肝损伤后4期胃癌伴腹膜播散的转化手术1例报告并文献复习

IF 0.5

International Cancer Conference Journal Pub Date : 2025-04-15 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00765-y

Yuto Kitano, Koji Okamoto, Kazushige Shibahara, Yoshiharu Tokimitsu, Yoshinobu Maeda

{"title":"Conversion surgery of stage 4 gastric cancer with peritoneal dissemination after overcoming immune-related liver injury: a case report and literature review.","authors":"Yuto Kitano, Koji Okamoto, Kazushige Shibahara, Yoshiharu Tokimitsu, Yoshinobu Maeda","doi":"10.1007/s13691-025-00765-y","DOIUrl":"https://doi.org/10.1007/s13691-025-00765-y","url":null,"abstract":"The prognosis for unresectable advanced gastric cancer remains poor. Chemotherapy is the primary treatment, and the recent introduction of immune checkpoint inhibitors (ICIs) has improved outcomes. Despite their benefits, ICIs can cause severe immune-related adverse events, necessitating careful administration. Conversion surgery, which involves radical resection after a positive response to chemotherapy, has shown better outcomes than chemotherapy alone. A 74-year-old woman presented with abdominal distension, and was diagnosed with advanced gastric cancer invading the transverse colon and causing obstruction. Radical resection was deemed difficult; hence, a bypass for colon obstruction was performed. Intraoperative assessments revealed transverse colon invasion, peritoneal dissemination, and positive results in lavage cytological examinations, confirming stage 4 gastric cancer. Postoperative chemotherapy with S-1, oxaliplatin, and nivolumab was initiated. She developed severe immune-related liver injury, responded to steroids, and resumed chemotherapy without nivolumab after recovery. After three cycles, significant tumor reduction and disappearance of peritoneal dissemination were observed. Conversion surgery, including right hemicolectomy and distal gastrectomy, was performed to achieve R0 resection. The patient was discharged on the ninth postoperative day and underwent adjuvant chemotherapy with S-1. She remained recurrence-free 18 months after surgery. This case demonstrated successful downstaging using chemotherapy with ICIs and subsequent radical resection via conversion surgery. Thus, conversion surgery is a viable option for multidisciplinary gastric cancer treatment and may see increased application with aggressive chemotherapy plus ICI regimens for managing metastatic or unresectable gastric cancer.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"212-219"},"PeriodicalIF":0.5,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delayed-onset immune-related colitis more than three years after nivolumab therapy for metastatic renal cell carcinoma: A case report. 纳沃单抗治疗转移性肾细胞癌后3年以上发生的延迟性免疫相关性结肠炎1例报告

IF 0.5

International Cancer Conference Journal Pub Date : 2025-04-12 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00762-1

Ken Shibata, Fumihiko Urabe, Gaku Kurokawa, Yuji Yata, Juria Nakano, Risako Ueha, Ruby Matsumoto, Makoto Okamoto, Hiroki Tanaka, Rie Ohtomo, Yusuke Koike, Takahiro Kimura

{"title":"Delayed-onset immune-related colitis more than three years after nivolumab therapy for metastatic renal cell carcinoma: A case report.","authors":"Ken Shibata, Fumihiko Urabe, Gaku Kurokawa, Yuji Yata, Juria Nakano, Risako Ueha, Ruby Matsumoto, Makoto Okamoto, Hiroki Tanaka, Rie Ohtomo, Yusuke Koike, Takahiro Kimura","doi":"10.1007/s13691-025-00762-1","DOIUrl":"https://doi.org/10.1007/s13691-025-00762-1","url":null,"abstract":"Nivolumab, a PD-1 inhibitor, enhances anti-tumor immunity but can cause immune-related adverse events (irAEs). Although irAE-colitis usually occurs within 2-3 months of starting nivolumab, we report a rare case that developed 38 months after treatment initiation. A 75-year-old man with metastatic renal cell carcinoma received multiple lines of molecular targeted therapies before starting nivolumab. After progression of bone metastases, nivolumab was reinitiated and maintained a complete response of bilateral iliac bone metastases for three years. He subsequently developed Grade 3 diarrhea. Colonoscopy revealed diffuse inflammation from rectum to sigmoid colon, and pathological examination showed findings consistent with irAE-colitis. Prompt initiation of prednisolone 60 mg/day led to complete symptom resolution within two weeks. This case represents the first reported instance of irAE-colitis occurring after 38 months of nivolumab treatment. It is essential to conduct regular follow-up examinations and actively perform diagnostic tests when symptoms arise, ensuring vigilance for the potential occurrence of delayed-onset irAEs to facilitate appropriate management.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"259-263"},"PeriodicalIF":0.5,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of zolbetuximab-induced protein-losing gastroenteropathy in a patient with advanced gastric cancer. 唑苯妥昔单抗致晚期胃癌患者失蛋白性胃肠病1例。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-04-11 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00764-z

Kunihiro Tsuji, Kito Yosuke, Saori Miyajima, Sho Tsuyama

引用次数: 0

Two Japanese patients with metastatic castration-resistant prostate cancer with somatic biallelic BRCA2 loss and RB1 splice site variant or loss who responded to Poly-ADP-ribose polymerase inhibitor: A case report. 2例日本转移性去势抵抗性前列腺癌患者，伴有体细胞双等位基因BRCA2缺失和RB1剪接位点变异或缺失，对poly - adp核糖聚合酶抑制剂有反应：1例报告。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-04-10 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00761-2

Shiori Miyachi, Takeshi Sasaki, Momoko Kato, Katsunori Uchida, Shunsuke Owa, Taketomo Nishikawa, Shinichiro Higashi, Hiroto Yuasa, Kouhei Nishikawa, Yoshinaga Okugawa, Masatoshi Watanabe, Takahiro Inoue

{"title":"Two Japanese patients with metastatic castration-resistant prostate cancer with somatic biallelic BRCA2 loss and RB1 splice site variant or loss who responded to Poly-ADP-ribose polymerase inhibitor: A case report.","authors":"Shiori Miyachi, Takeshi Sasaki, Momoko Kato, Katsunori Uchida, Shunsuke Owa, Taketomo Nishikawa, Shinichiro Higashi, Hiroto Yuasa, Kouhei Nishikawa, Yoshinaga Okugawa, Masatoshi Watanabe, Takahiro Inoue","doi":"10.1007/s13691-025-00761-2","DOIUrl":"10.1007/s13691-025-00761-2","url":null,"abstract":"We treated two patients with metastatic castration-resistant prostate cancer (mCRPC) who achieved a response duration of more than 12 months with Poly-ADP-ribose polymerase inhibitor (PARPi). Case 1 was a patient in his 60s with lung metastases, and case 2 was in his 70s and presented liver metastases. Genetic tests (FoundationOne® CDx) were performed. Both patients had somatic biallelic BRCA2 loss, together with RB1 splice site variant (NM_000321.3:c.2489 + 1G > C) or RB1 loss. After PARPi administration, their metastatic sites had shrunk enough to keep partial response. These cases suggested that patients with mCRPC with biallelic BRCA2 loss and the RB1 splice site variant or loss may have remarkable response to PARPi.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"254-258"},"PeriodicalIF":0.5,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0